300158 Shanxi Zhendong Pharmaceutical
- 4.47
- +0.04+0.90%
Shanxi Zhendong Pharmaceutical News
Zhendong Pharmaceutical (300158): Foreign Investment Rating (FIR)
Zhendong Pharmaceutical (300158) Annual Report Review: Kangyuan's Merger Drives Rapid Performance Growth
Zhendong Pharmaceutical (300158) Quarterly report comments: Kangyuan's rapid growth drives continuous improvement in profitability
Zhendong Pharmaceutical (300158) semi-annual report comments: performance in line with expectations and Kangyuan table to promote profitability
Zhendong Pharmaceutical (300158): and Kangyuan contributed performance and regained the advantage of old varieties.
Zhendong Pharmaceutical (300158): The Lion Dynasty of Traditional Chinese Medicine continues to be the leader in calcium supplementation
Comments on Zhendong Pharmaceutical (300158) Annual report: income growth exceeds expectations to achieve equity incentive target
[Minsheng Securities] Zhendong Pharmaceutical's 2016 Annual Performance Forecast Review: Consolidated performance increases, future growth is clear
Zhendong Pharmaceutical (300158): and thickened performance clear future growth
Zhendong Pharmaceutical (300158): the old variety withered wood in spring and Kangyuan added wings like a tiger.
Zhendong Pharmaceutical (300158) Third Quarterly Report Review: Business Has Blossomed More and Increased Performance
Zhendong Pharmaceutical (300158): Acquisition of Kangyuan to power OTC Yanshu ushered in new opportunities
振东制药(300158)年报点评：拐点明确 盈利能力有望不断提升
[Shen Wan Hongyuan] Zhendong Pharmaceutical: The inflection point is clear, and profitability is expected to continue to improve
Event: The company released its 2014 annual report and achieved annual revenue of 1,919 billion yuan, an increase of 15.74% over the previous year. Non-net profit was reduced by 20.27 million yuan, a year-on-year decrease of 72.90%. Earnings per share were
[Northeast Securities] Zhendong Pharmaceutical: Still in a period of transformation and adjustment
[Northeast Securities] Zhendong Pharmaceutical: Equity Incentives Announced, Rapid Growth Expected
Zhendong Pharmaceutical (300158): Equity Incentives Announced Rapid Growth Can Be Expected
Commentary on the quarterly report of Zhendong Pharmaceutical (300158): The decline in Q1 performance is abnormal, and high growth is still expected throughout the year
[Northeast Securities] Zhendong Pharmaceutical: The decline in Q1 performance is abnormal, and high growth is still expected throughout the year
Analysis
Price Target
No Data
